Welcome to DukeHealth.org.
Skip over navigation
  • Home
  • Patient and Visitor Info
  • Physicians
  • Services
  • Clinical Trials
  • Event Calendar
  • Locations
  • Health Library
  • About Duke Medicine

Quick Links

  • Appointments
  • HealthView Patient Login
  • Quality and Safety
Home > Clinical Trials > RED-HF: Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF)
Jumbo Large Regular Text:
Print
Clinical Trials

RED-HF: Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF)

Related Content

Health Articles

  • Understanding Clinical Trials: A participants' guide

In This Section

Related Clinical Trials

  • Heart Failure

Share

The purpose of this study is to compare the safety and effectiveness of darbepoetin alfa (Aranesp) to a placebo (an injection containing no medication) in patients with heart failure.

The trial is scheduled to last three years.

For more information, contact Patricia Adams, RN, at 919-668-7184.


(REF# 9437)
Contact Us | Careers | Privacy Policy | Make a Gift | Site Map | RSS Feeds | En EspaƱol | Mobile Site | Help
Duke Medicine | Duke School of Medicine | Duke Children's | Duke University
Toll-Free: 888-ASK-DUKE (888-275-3853)
Copyright © 2004-2013 Duke University Health System

About This Page

Updated: June 6, 2011
Published: June 6, 2011
URL: http://www.dukehealth.org/clinicaltrials/red-hf-darbepoetin-alfa-on-mortality-and-morbidity-in-heart-failure